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Pathogenesis of secondary hyperparathyroidism. Secondary third the number of VDR compared to parathyroid ade-
hyperparathyroidism is a universal complication in patients nomas. Merke et al [4] found that in rats, six days after
with chronic renal failure. Hyperplasia of the parathyroid subtotal nephrectomy, parathyroid glands contained onlyglands is typically seen in these patients. In early renal failure,
half the number of receptors compared to PTG of sham-alteration in vitamin metabolism, decreased levels of calcitriol
operated controls. Similar results were found by Brownand moderate decreases in ionized calcium may allow greater
synthesis and secretion of PTH. As the disease progresses, et al in dogs [5]. Although it has not been previously
there is a decrease in the number of vitamin D receptors (VDR) proven that VDR plays a role in suppressing PTH syn-
and calcium receptors (CaR). The decreased number of VDR thesis and determining the set-point for calcium, it isand CaR makes the parathyroid glands more resistant to
possible that the reduced VDR number in the parathy-calcitriol and calcium. Phosphorus induces hyperplasia of the
roid glands of uremic patients renders the glands lessparathyroid glands independent of calcium and calcitriol, and
by a post-transcriptional mechanism increases PTH synthesis responsive to the inhibitory action of 1,25D. 1,25(OH)2D3
and secretion. Experimental work in uremic rats demonstrated plays an important role in the content of the VDR in
that if the animals are fed a high-phosphorus diet, they not only
several tissues. Binding of 1,25D stabilizes the VDR anddeveloped secondary hyperparathyroidism but parathyroid cell
the half-life of the receptor is increased [6]. In the PThyperplasia. If the diet is then reduced in phosphorus, the
levels of PTH return to normal. However, the parathyroid cell glands and kidney, 1,25D also up regulates VDR mRNA.
hyperplasia persists and no apoptosis is seen. Thus, the control This data is consistent with the view that 1,25D regulates
of the three most important factors, calcium, calcitriol and its own receptor in parathyroid cells. 1,25(OH)2D3 mayphosphorus, is critical to prevent the development of secondary
be an important regulator of parathyroid cell growthhyperparathyroidism and hyperplasia of the parathyroid glands.
and low levels of 1,25D may allow parathyroid cells to
proliferate. Studies by Szabo et al [7] in experimental
animals with renal failure suggest that 1,25D administra-Hyperplasia of the parathyroid glands and high levels
tion suppresses parathyroid hyperplasia, perhaps throughof serum parathyroid hormone (PTH) are among the
changes in serum calcium. However, once established,most consistent pathogenetic factors affecting divalent
PT hyperplasia was not reversed by short-term 1,25Dion metabolism in patients with chronic renal failure.
treatment. Fukuda et al [8] have provided evidence forIncreased serum levels of PTH occur even in patients
decreased 1,25D receptor density in patients with para-with mild to moderate renal impairment, recognized as
thyroid hyperplasia. These investigators studied theearly as the 1960s [1, 2]. Serum ionized calcium, 1,25-
VDR distribution of surgically excised PTG obtaineddihydroxyvitamin D3 (1,25D), and phosphorus are the
from dialysis patients. They classified the parathyroidthree main regulators of PTH in man. (Fig. 1)
glands as exhibiting nodular or diffuse hyperplasia. They
found a lower density of the VDR in PTG showing nodu-
ALTERATIONS IN VITAMIN D METABOLISM lar hyperplasia than in those showing diffuse hyperplasia.
ON PTH SECRETION AND PARATHYROID A significant correlation was found between VDR den-
GLAND GROWTH IN RENAL FAILURE sity and the weight of the parathyroid gland. In other
The control of PTH gene transcription by 1,25D is medi- words, the higher the levels of PTH in serum, the greater
ated by the vitamin D receptor (VDR), a protein with the degree of parathyroid gland hyperplasia and the
high affinity and specificity for the vitamin D hormone. lower the density of the VDR. This study provides a
Korkor [3] demonstrated that parathyroid glands (PTG) rational basis for understanding the difficulties in sup-
from patients with chronic renal failure contained one- pressing secondary hyperparathyroidism (SH) when the
PTH levels are extremely high (.1500). In addition, it
is important to emphasize that in the PTG there is aKey words: chronic renal failure, calcium, calcitriol, phosphorus, para-
thyroid hormone. component of the secretory mechanism that can not be
suppressed by either high calcium or pharmacological 1999 by the International Society of Nephrology
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Fig. 2. Effects of 1,25(OH)2D3 and 22-oxacalcitriol (OCT) on vitamin
D receptor content in parathyroid glands. Normal control rats (N 5 9),
uremic control rats (N 5 15), uremic rats receiving 2 or 6 ng of
1,25(OH)2D3 (N 5 15 for each group), and uremic rats receiving 8 or
50 ng of OCT (N 5 15 for each group). *P , 0.05 vs. uremic control.
(Reproduced with permission from 11).
Fig. 1. Schematic representation of the factors involved in the patho-
genesis of secondary hyperparathyroidism.
a known vitamin D responsive element (VDRE) using
electrophoretic mobility shift assays (EMSA). Analysis
of the data indicates that the ultra-filtrate did not affectdoses of 1,25D [9,10]. Although this component of secre-
the affinity of the binding but rather reduced a fraction oftion represents a small percentage of the total amount
the VDR capable to binding to the VDRE. 1,25(OH)2D3of PTH in normal individuals, it becomes extremely im-
may also be critical in the full responsiveness of theportant in patients in which the PTG are 50–100 times
parathyroid glands to calcium. Regulation of the calciumthe normal size. Recently, Denda et al [11] showed a
receptor of the rat parathyroid gland by 1,25D has beenstrong correlation between serum 1,25D levels and VDR
reported by some authors [14]. Vitamin D deficiencybinding activity in the parathyroid glands of uremic rats
decreased and 1,25D treatment increased the calciumsuggesting that the decreased VDR content may be re-
sensing receptor mRNA.lated to low levels of 1,25D. Moreover, low doses of
Clinical observations suggest that therapy with 1,25D1,25D (2 or 6 ng three times per week) or the administra-
to control PTH is difficult in chronic renal failure patientstion of 22-oxa-calcitriol, a noncalcemic analog of vitamin
having hyperphosphatemia. The nature of this resistance
D, increased the vitamin D receptor content in the PT
to 1,25D is unclear and may involve several alterations
glands to normal levels (Fig. 2). Resistance to 1,25D in
in the parathyroid gland such as VDR content, calcium
chronic renal failure also appears to be mediated by receptor expression and/or activation of the parathyroid
impaired VDR transcriptional activity. Patel et al [12] cell cycle.
had presented evidence that components in the blood
of renal failure patients diminished the ability of the
THE ROLE OF CALCIUMVDR receptor to bind vitamin D responsive elements
in the DNA of target genes. Intestinal VDR receptor Evidence exists for an intrinsic abnormality of the
from uremic rats was found to elute from DNA cellulose PTG in uremia that leads to a disordered calcium-regu-
at a lower salt concentration, indicating a reduced affinity lated PTH secretion and insensitivity to the suppressive
for DNA. Nuclear uptake studies performed in vitro effect of calcium on PTH secretion in glands obtained
showed that intestinal VDR from uremic rats was taken from patients with chronic renal failure [15]. These ob-
up to a lesser extent than the vitamin D receptor from servations suggest that one mechanism for the increased
normal rat intestine. When normal VDR was incubated PTH levels in chronic renal failure may be a shift in the
with uremic plasma ultra-filtrate nuclear uptake in vitro set-point for calcium regulated PTH secretion in addition
was inhibited. Patel et al [13] determined the effect of to the increase in the mass of parathyroid tissue. These
abnormalities are also manifested by an increase in theuremic plasma ultra-filtrate on the binding of VDR to
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calcium concentration required for the inhibition of the with primary and secondary hyperparathyroidism. In situ
adenylate cyclase activity in membranes prepared from hybridization techniques and histomorphometry demon-
hyperplastic PTG obtained from patients with chronic strated a significant decrease in the number of calcium
renal failure [16]. Although Brown et al [15] clearly dem- receptors in both abnormal parathyroid tissues. In addi-
onstrated this abnormality of the set-point for calcium tion, they observed the lowest calcium receptor expres-
in vitro in parathyroid tissue obtained from patients with sion in nodular portion of the gland, is the most patholog-
chronic renal failure, when studies were performed in ical one, as far as decrease in the number of calcium
vivo, the results proved controversial since several au- and vitamin D receptors. Thus, it appears that the more
thors were unable to demonstrate an abnormal set-point. rapidly proliferating nodules have the greatest decrease
This might in part relate to the way PTH is secreted: it in VDR and calcium receptor and are likely resistant to
is partly rate-dependent (DCa/dt) and partly pulsatile. suppression by calcium and 1,25D.
The initial secretory response of the PTG to hypocal-
cemia occurs within 1–3 minutes, suggesting that calcium
ROLE OF PHOSPHORUS ON THEacts directly on the plasma membrane. The mechanism
REGULATION OF PTH SYNTHESISof this effect may be related, at least in part, to an effect
AND SECRETIONof calcium on parathyroid cell membrane potential. An
additional effect of calcium secretion may also be a con- Reiss et al [22] reported that the administration of
sequence of the regulation of the amount of hormone one gram of elemental phosphorus led to an increase in
available for secretion as a result of the calcium dose serum phosphorus, a decrease in ionized calcium and an
dependent regulation of hormone degradation within increase in serum PTH in normal subjects. Studies in
the parathyroid gland. Brown et al [17] cloned a calcium experimental renal failure in dogs have shown that a
receptor localized in bovine parathyroid cell membranes. restriction of dietary phosphorus in proportion to the
Parathyroid cells possess a calcium sensing mechanism decrease in GFR can prevent the development of sec-
that recognizes trivalent and polyvalent cations such as ondary hyperparathyroidism [23]. In addition to a de-
(neomycin) and regulates PTH secretion by changes in crease in the levels of ionized calcium, high serum phos-
phosphoinositide turnover and cytosolic calcium. This phorus decreases the production of 1,25(OH)2D3. As
receptor features a large extracellular domain containing renal disease advances and GFR falls below 25 ml/min,
clusters of acidic amino acid that are possibly involved hyperphosphatemia is present in most patients and hypo-
in calcium binding. The extracellular domain is coupled calcemia is more directly related to the markedly in-
to a cellular seven membrane-spanning domain similar creased levels of serum phosphorus. Although high con-
to the G-protein coupled receptor superfamily. Pollack centrations of serum phosphorus (7–9 mg/dl) precipitate
et al [18] demonstrated that mutations of the human calcium in soft tissue, the mechanism by which hyper-
calcium sensing receptor caused familiar hypocalciuria, phosphatemia affects the concentration of ionized cal-
hypercalcemia, and severe neonatal hyperparathyroidism.
cium is not known. It may decrease the release of calcium
Calcium can also regulate PTH gene transcription.
from bone [24] and/or affect the activity of the renalOkazaki et al [19] identified a negative regulatory ele-
enzyme 1-hydroxylase that converts 25-hydroxy vitaminment located 3.5 kb upstream from the transcriptional
D to 1,25(OH)2D3. Since reduced renal mass may limitstart site in the PTH gene that modulates the transcrip-
the production of 1,25D in advanced renal insufficiency,tional suppression of PTH by extracelluar calcium. Thus,
we performed studies in uremic dogs to clarify the mech-several factors can lead to elevated serum parathyroid
anism by which dietary phosphate restriction improveshormone levels in man. This includes 1) an increase in
secondary hyperparathyroidism [25]. After six monthstissue mass either from cell hypertrophy and/or hyper-
of renal insufficiency the dogs developed significant sec-plasia; 2) an increase in the set-point for calcium; and
ondary hyperparathyroidism. Thereafter, we gradually3) a change in the degree of suppression by calcium
decreased the amount of phosphorus in the diet fromthroughout the calcium sensitive range (e.g., slope of the
0.9 to 0.6, 0.45, and finally 0.3%. In addition, the amountsuppression line). Kifor et al [20], using immunochemis-
of calcium in the diet was reduced from 1.6 to 0.6% totry techniques, demonstrated a 59% decrease in calcium-
prevent the development of hypercalcemia. As expected,sensor receptor in parathyroid glands of uremic patients.
by restricting dietary phosphorus there was a concomi-Similar results were demonstrated in adenomas of para-
tant decrease in the levels of serum phosphorus and sincethyroid glands obtained from patients with primary hy-
dietary calcium was decreased from 1.6 to 0.6% thereperparathyroidism. These investigators concluded that
was also a mild decrease in ionized calcium. Althoughthe degree of calcium receptor reduction would be suffi-
no change was observed in the levels of 1,25D, therecient to account, at least in part, for the altered sensitivity
was a significant decrease in the levels of PTH. Thus,to calcium observed in secondary hyperparathyroidism.
Gogusev et al [21] obtained similar results in patients this study clearly indicates that phosphorus per se, inde-
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pendent of the levels of serum calcium and 1,25D has
an important effect on the regulation of PTH secretion.
CURRENT STUDIES
More recently, Naveh-Many et al [26] demonstrated
that parathyroid cell proliferation was greatly enhanced
by a high phosphorus diet and markedly decreased by a
low phosphorus diet in rats with 5/6 nephrectomy. The
number of cells expressing proliferating cell nuclear anti-
gen (PCNA) was increased by a high phosphorus diet.
The authors concluded that hypocalcemia, hyperphos-
phatemia and uremia led to parathyroid cell proliferation
and hypophosphatemia completely abolished PT hyper-
plasia in uremic rats. Similar results were found by Wang
et al [27].
We studied in great detail the effect of phosphorus on
PTH secretion in vivo in rats with chronic renal insuffi-
ciency and in vitro with disperse bovine parathyroid cells,
primary cultures of bovine parathyroid cells and intact Fig. 3. Time course for PTH secretion by normal intact parathyroid
glands, incubated in a low (0.2 mM) (s) (N 5 8) or high (2.8 mM) (d)parathyroid glands from normal rats [28]. It appears that
(N 5 8) phosphorus in the media (P , 0.05). The effects of phosphorusin either short-term studies with dispersed cells or in were not evident until 3 hr. (Reproduced with permission of J Clin
primary culture of bovine parathyroid cells phosphorous Invest 28).
does not affect PTH secretion. We speculate that cell to
cell contact or cell–matrix interaction may be necessary
for the effect of phosphorus on PTH secretion. This
about a direct effect of phosphorus on PTH synthesisconcept is supported by our studies with intact parathy-
and secretion. In the past five years, several groups ofroid glands from normal rats. Short-term experiments
investigators have further advanced our knowledge on(1 hr) did not show any effect of high (2.8 mm) phospho-
the effect of phosphorus in the development of secondaryrus in the medium on the secretion of PTH. Thus, we
hyperparathyroidism and chief cell hyperplasia in animalperformed long-term incubations over a period of 6 hr
models of chronic renal failure. Our studies also have(Fig. 3). After 3 hr of incubation there was a significant
demonstrated an effect of phosphorus on parathyroidincrease in PTH secretion by the glands incubated in a
cell growth. Similar results were reported by Naveh-medium containing 2.8 vs. 0.2 mm P. These results suggest
Many [26]. Yi et al [32] studied the effect of phosphorusthat phosphorus alters the rate of PTH synthesis and
restriction on secondary hyperparathyroidism and para-subsequently secretion. There was no effect of phospho-
thyroid hyperplasia in 5/6 nephrectomized rats. Therus on PTH/GAPDH -mRNA after 24, 48 or 72 hr of
amount of phosphorus in the diet varied from 0.6 andincubation, consistent with our finding in vivo [28]. These
0.3 to 0.1%. The investigators found that the rats fed aresults suggest that the effect of phosphorus is post-
0.3% phosphorus diet did not develop secondary hyper-transcriptional. This was confirmed by other investiga-
parathyroidism; serum levels of calcium, phosphorus andtors [29] performing nuclear “run off” studies. Almaden
1,25(OH)2D3 were no different from those seen in normalet al [30] also have shown a direct effect of phosphorus
rats. Their results suggest that secondary hyperparathy-on PTH secretion from whole rat parathyroid glands in
roidism and parathyroid cell proliferation can be com-vitro. These investigators have shown that, in a medium
pletely prevented by a mild dietary phosphorus restrictioncontaining 1 or 2 mm P, an increase in calcium from 0.6
(0.3%) and that such effects may not depend upon changesto 1.35 mm reduced PTH secretion by 63%, while in the
in serum concentration of calcium, or 1,25(OH)2D3. Thepresence of 4 mm P, the same increase in calcium inhib-
time course for the effect of phosphorus on parathyroidited PTH secretion by only 25%. Consistent with our
gland weight was further studied by Denda et al [33].studies, Nielsen et al [31] demonstrated a direct effect
These investigators demonstrated that in rats on a highof phosphorus on PTH release from bovine parathyroid
phosphorus diet there was a 60–80% increase in thetissue slices. However they found no effect on dispersed
size of the parathyroid gland by 3–5 days after inducingbovine parathyroid cells. It would seem that cell to cell
uremia. Although the glands further increased after onecontact or cell–matrix interaction is crucial for the effect
month of renal insufficiency most of the growth occuredof phosphorus on PTH secretion. Thus, there is now
agreement in the literature based on these in vitro studies in the first week. There was an increase in parathyroid
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it is not known how phosphorus induces PTH synthesis
or parathyroid gland hyperplasia. Since Denda et al [33]
demonstrated that the effect of phosphorus on parathy-
roid cell growth in uremic rats is very rapid, i.e., most
of the growth occurring in the first five days, protoonco-
genes such as c-fos, c-jun and PRAD-1 [34–36] may play
a role in the growth of the parathyroid glands. It is well
known that normal parathyroid cells rarely divide and
the great majority of cells remain in a quiescent state
(G0). Nevertheless, they have the potential to proliferate
in response to mitogenic stimuli such as uremia, high
phosphorous or low calcium. Parathyroid cell prolifera-
tion results from the cell commitment to abandon G0,
cross the restriction point and complete the mitotic cycle.
This decision is made in early G1 and depends upon theFig. 4. The effects of a high phosphorus diet on parathyroid gland
weight, protein and DNA in uremic rats. Weight, j; protein, s; net balance between two opposite forces: 1) the cyclin
DNA, d. (Modified from [33]). and cyclin-dependent kinases, responsible for the cell
progression through the consecutive phases of the cycle,
and 2) the levels of inhibitors of the activity of the cyclin-
cdk complexes. One important inhibitor of the cell cyclegland weight, protein and DNA indicating hyperplasia
is P21. In our laboratory Dusso et al (abstract; J Am Socwas the main factor responsible for the parathyroid cell
Nephrol 9:564A, 1998) have demonstrated that the levelsgrowth (Fig. 4). Takahashi et al (abstract; J Am Soc
of P21 mRNA and protein are increased after two daysNephrol 8:580A, 1997) demonstrated that once the para-
of uremia in animals maintained on a low phosphorusthyroid glands were enlarged in uremic rats, a low phos-
diet, suggesting a role for P21 in the suppression of para-phorus diet returned the parathyroid hormone to normal.
thyroid cell proliferation by a low phosphorus diet.However, the parathyroid glands remained enlarged.
Two recent observations may provide further insightThese investigators demonstrated that in uremic rats, two
into how phosphorus affects PTH synthesis/secretion.weeks of a high phosphorus diet significantly increased
Tasumi et al [37] cloned a Na1–dependent Pi cotrans-
serum parathyroid hormone from 32 to 160 pg/ml, and
porter (PiT-1) from rats parathyroid glands. The amount
the size of the parathyroid gland increased from 0.7 6 of PiT-1 mRNA in parathyroid glands of vitamin
0.06 to 1.20 6 0.09 mg/g of body weight (P , 0.001). d-deficient rats was reduced compared with that in nor-
When the uremic rats on a high phosphorus diet were mal animals, but increased markedly after the adminis-
switched to a low phosphorus diet for only one week, tration of 1,25(OH)2D3. Since 1,25D suppresses PTH se-both serum phosphorus and PTH returned to normal. cretion and phosphorus enhances PTH secretion, the
However, the size of the glands did not decrease and physiological role of the Na1-dependent P1 cotransporter
there was no apoptosis. The intracellular PTH content in the regulation of PTH secretion is unclear. Mollem et
was similar in the two groups of uremic rats. These results al [38] demonstrated that parathyroid cytosolic proteins
suggest that 1) the parathyroid gland PTH content corre- bind the 39-untranslated region (UTR) of the PTH
lates only with parathyroid gland weight and DNA re- mRNA. These parathyroid proteins showed increased
gardless of the phosphate content of the diets; 2) the binding in hypocalcemia and decreased binding in hypo-
low phosphorus diet does not affect the synthesis of PTH phosphatemia. The decreased binding will enhance the
in glands with established chief cell hyperplasia; and 3) degradation of the PTH mRNA and therefore shorten
the effect of the low phosphorus diet on PTH content in the life of the transcript during hypophosphatemia.
the parathyroid gland is independent of the mechanism Thus, in the past 20 years numerous investigators have
regulated by ionized calcium. Thus, by switching the diet provided strong evidence for the action of phosphorus
from high phosphorus to low phosphorus, the glands on PTH secretion. There is agreement that the mecha-
remained increased in size, but the levels of serum PTH nisms of action of phosphorus on PTH synthesis and
returned to normal indicating that there is hyperplasia secretion is post-transcriptional. Moreover, the rate of
of the parathyroid glands without secondary hyperpara- parathyroid cell proliferation also is greatly enhanced by
thyroidism. Currently, we are studying at a molecular phosphorus. Unfortunately, the absence of a parathyroid
level potential mechanism(s) responsible for the dissoci- cell line is slowing the progress in understanding the
ation between the histologic changes in the parathyroid molecular mechanism(s) involved in the regulation of
gland and the secretory mechanisms of parathyroid hor- PTH secretion and parathyroid gland hyperplasia by
phosphorus.mone with phosphorus restriction. As we described above,
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hypercalcemia and neonatal severe hyperparathyroidism. CellACKNOWLEDGMENTS
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